Infections Associated With the Use of Alemtuzumab

Completed

• Conditions: Patients Treated With Alemtuzumab

• Registration Number: NCT01315457
• Lead Sponsor: Samsung Medical Center

Brief Summary

The aim of this study is to propose infection prophylaxis from Asian multinational retrospective analysis of infectious complications in patients who were treated with alemtuzumab

Detailed Description

Not available

Study Timeline

• Study Start: 2009-04
• Study First Submitted: 2011-03-13
• Study First Submitted QC: 2011-03-13
• Study First Posted: 2011-03-15
• Primary Completion: 2012-03
• Study Completion: 2012-03
• Status Verified: 2012-05
• Last Update Submitted: 2012-05-22
• Last Update Posted: 2012-05-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 182

Inclusion Criteria

• Patients received alemtuzumab as a treatment for hematologic malignancy ex. non-Hodgkin lymphoma Acute myeloid leukemia Aplastic anemia

Exclusion Criteria

• Patients did not receive alemtuzumab

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Infectious event	one year	Any infectious complication occurred within one year after the use of alemtuzumab

Trial Locations

Locations (5)

Cipto Mangunkusumo General Hospital; 🇮🇩 Jakarta, Indonesia

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of

Queen Mary Hospital; 🇨🇳 Hong Kong, China

National Taiwan University Hospital; 🇨🇳 Teipei, Taiwan

Chulalongkorn University; 🇹🇭 Bangkok, Thailand